AbbVie Inc. (ABBV)
NYSE: ABBV
· Real-Time Price · USD
185.07
-0.42 (-0.23%)
At close: Jun 20, 2025, 3:59 PM
185.54
0.25%
Pre-market: Jun 23, 2025, 04:56 AM EDT
AbbVie Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Botox Cosmetic Revenue | 2.72B | 2.68B | 2.62B | 2.23B | 1.11B | 2.89B | 3.44B | 355M | 293M | 231M | 220M | 178M |
| Botox Cosmetic Revenue Growth | +1.42% | +2.56% | +17.16% | +100.72% | -61.56% | -15.85% | +868.45% | +21.16% | +26.84% | +5.00% | +23.60% | n/a |
| Juvederm Collection Revenue | 1.18B | 1.38B | 1.43B | 1.53B | 718M | 4.67B | 3.59B | 18.43B | 16.08B | 14.01B | 12.54B | 1.67B |
| Juvederm Collection Revenue Growth | -14.59% | -3.50% | -6.97% | +113.79% | -84.64% | +30.19% | -80.52% | +14.61% | +14.74% | +11.71% | +652.88% | n/a |
| Other Aesthetics Revenue | 1.28B | 1.23B | 1.29B | 1.47B | 760M | 792M | 344M | 2.57B | 1.83B | 754M | 1.63B | n/a |
| Other Aesthetics Revenue Growth | +3.65% | -4.34% | -12.01% | +92.89% | -4.04% | +130.23% | -86.63% | +40.45% | +142.97% | -53.71% | n/a | n/a |
| Alphagan/Combigan Revenue | 248M | 272M | 346M | 529M | 326M | 19.17B | 19.94B | 998M | 1.22B | 1.22B | n/a | n/a |
| Alphagan/Combigan Revenue Growth | -8.82% | -21.39% | -34.59% | +62.27% | -98.30% | -3.85% | +1897.60% | -18.00% | -0.49% | n/a | n/a | n/a |
| Lumigan/Ganfort Revenue | 429M | 432M | 514M | 579M | 378M | 47M | 430M | n/a | n/a | n/a | n/a | n/a |
| Lumigan/Ganfort Revenue Growth | -0.69% | -15.95% | -11.23% | +53.17% | +704.26% | -89.07% | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Eye Care Revenue | 847M | 803M | 1.18B | 1.17B | 693M | 355M | 319M | n/a | n/a | n/a | n/a | n/a |
| Other Eye Care Revenue Growth | +5.48% | -31.66% | +0.51% | +68.69% | +95.21% | +11.29% | n/a | n/a | n/a | n/a | n/a | n/a |
| Ozurdex Revenue | 494M | 472M | 666M | 1.29B | 787M | 461M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ozurdex Revenue Growth | +4.66% | -29.13% | -48.37% | +63.91% | +70.72% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Restasis Revenue | 224M | 436M | 4.57B | 5.41B | 5.31B | 511M | n/a | n/a | n/a | n/a | n/a | n/a |
| Restasis Revenue Growth | -48.62% | -90.46% | -15.53% | +1.77% | +939.92% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Imbruvica Revenue | 3.35B | 3.6B | 2.01B | 1.82B | 1.34B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Imbruvica Revenue Growth | -6.92% | +78.99% | +10.38% | +36.13% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| VENCLEXTA Revenue | 2.58B | 2.29B | 21.24B | 20.69B | 19.83B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| VENCLEXTA Revenue Growth | +12.89% | -89.23% | +2.62% | +4.35% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| H U M I R A Revenue | 8.99B | 14.4B | 2.52B | 1.65B | 731M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| H U M I R A Revenue Growth | -37.57% | +471.13% | +52.76% | +125.85% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| RINVOQ Revenue | 5.97B | 3.97B | 5.17B | 2.94B | 1.59B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| RINVOQ Revenue Growth | +50.44% | -23.16% | +75.74% | +84.84% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| SKYRIZI Revenue | 11.72B | 7.76B | 2.72B | 2.45B | 1.39B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| SKYRIZI Revenue Growth | +50.95% | +185.51% | +10.93% | +76.71% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Botox Therapeutic Revenue | 3.28B | 2.99B | 458M | 511M | 494M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Botox Therapeutic Revenue Growth | +9.76% | +553.06% | -10.37% | +3.44% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Duodopa Revenue | 447M | 468M | 475M | 685M | 539M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Duodopa Revenue Growth | -4.49% | -1.47% | -30.66% | +27.09% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Neuroscience Revenue | 338M | 276M | 2.04B | 1.04B | 667M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Neuroscience Revenue Growth | +22.46% | -86.46% | +96.34% | +55.62% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Qulipta Revenue | 658M | 408M | 1.03B | 1.71B | 1.83B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Qulipta Revenue Growth | +61.27% | -60.58% | -39.47% | -6.56% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ubrelvy Revenue | 1.01B | 815M | 1.54B | 2.67B | 2.92B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ubrelvy Revenue Growth | +23.44% | -47.11% | -42.35% | -8.55% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Vraylar Revenue | 3.27B | 2.76B | 4.14B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Vraylar Revenue Growth | +18.41% | -33.31% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Linzess/Constella Revenue | 954M | 1.11B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Linzess/Constella Revenue Growth | -13.90% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| MAVYRET Revenue | 1.31B | 1.43B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| MAVYRET Revenue Growth | -8.32% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Products Revenue | 3.03B | 3.04B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Products Revenue Growth | -0.10% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia Revenue | 463M | 472M | 508M | 533M | 527M | 359M | 350M | 410M | 355M | 4B | 3.27B | 439M |
| Australia Revenue Growth | -1.91% | -7.09% | -4.69% | +1.14% | +46.80% | +2.57% | -14.63% | +15.49% | -91.13% | +22.28% | +645.33% | n/a |
| Brazil Revenue | 464M | 439M | 430M | 368M | 406M | 813M | 730M | 659M | 624M | n/a | n/a | 538M |
| Brazil Revenue Growth | +5.69% | +2.09% | +16.85% | -9.36% | -50.06% | +11.37% | +10.77% | +5.61% | n/a | n/a | n/a | n/a |
| Canada Revenue | 1.09B | 1.08B | 1.16B | 1.4B | 1.16B | 695M | 783M | 730M | 713M | n/a | n/a | 540M |
| Canada Revenue Growth | +1.12% | -7.16% | -17.04% | +20.53% | +66.76% | -11.24% | +7.26% | +2.38% | n/a | n/a | n/a | n/a |
| China Revenue | 917M | 950M | 912M | 857M | 471M | 909M | 1.29B | 1.16B | 1.1B | n/a | n/a | 911M |
| China Revenue Growth | -3.47% | +4.17% | +6.42% | +81.95% | -48.18% | -29.64% | +11.67% | +4.80% | n/a | n/a | n/a | n/a |
| France Revenue | 776M | 780M | 787M | 936M | 797M | 372M | 652M | 475M | 523M | n/a | n/a | 404M |
| France Revenue Growth | -0.51% | -0.89% | -15.92% | +17.44% | +114.25% | -42.94% | +37.26% | -9.18% | n/a | n/a | n/a | n/a |
| Germany Revenue | 1.47B | 1.27B | 1.34B | 1.22B | 1.05B | 1.21B | 1.59B | 764M | 770M | n/a | n/a | 625M |
| Germany Revenue Growth | +15.72% | -5.52% | +9.57% | +16.59% | -13.38% | -23.88% | +108.25% | -0.78% | n/a | n/a | n/a | n/a |
| Italy Revenue | 511M | 484M | 444M | 506M | 379M | 3.99B | 4.01B | 4.08B | 3.88B | n/a | n/a | 3.15B |
| Italy Revenue Growth | +5.58% | +9.01% | -12.25% | +33.51% | -90.51% | -0.50% | -1.64% | +5.02% | n/a | n/a | n/a | n/a |
| Japan Revenue | 1.12B | 1.01B | 956M | 1.09B | 1.2B | 472M | 611M | 521M | 589M | n/a | n/a | 543M |
| Japan Revenue Growth | +11.31% | +5.44% | -12.29% | -9.02% | +153.81% | -22.75% | +17.27% | -11.54% | n/a | n/a | n/a | n/a |
| Other Countries Revenue | 5.45B | 5.04B | 4.84B | 4.76B | 3.98B | n/a | n/a | 18.25B | 15.95B | n/a | n/a | 10.18B |
| Other Countries Revenue Growth | +8.07% | +4.24% | +1.60% | +19.71% | n/a | n/a | n/a | +14.45% | n/a | n/a | n/a | n/a |
| Spain Revenue | 528M | 501M | 506M | 519M | 453M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Spain Revenue Growth | +5.39% | -0.99% | -2.50% | +14.57% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue | 43.03B | 41.88B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +2.74% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 3.29B | 3.85B | 4.21B | 3.34B | 3.3B | 3.61B | 3.37B | 3.27B | 3.04B | 3.42B | 3.3B | 5.41B | 3.13B | 3.26B | 3.08B | 3.16B | 2.84B | 3.23B | 2.85B | 3.53B | 1.7B | 1.95B | 1.66B | 1.65B | 1.68B | 1.93B | 1.92B | 1.76B | 1.79B | 1.95B | 1.45B | 1.5B | 1.37B | 1.65B | 1.38B | 1.47B | 1.35B | 1.74B | 1.47B | 1.7B | 1.47B |
| Selling, General, and Administrative Revenue Growth | -14.58% | -8.32% | +25.82% | +1.27% | -8.49% | +6.94% | +3.18% | +7.54% | -11.06% | +3.42% | -38.95% | +73.07% | -4.08% | +5.74% | -2.56% | +11.33% | -12.04% | +13.53% | -19.31% | +108.08% | -13.12% | +17.74% | +0.18% | -1.55% | -12.91% | +0.52% | +9.03% | -1.73% | -8.20% | +34.37% | -3.46% | +9.94% | -17.24% | +19.70% | -5.80% | +8.19% | -21.99% | +17.84% | -13.45% | +15.61% | n/a |
| Research and Development Revenue | 2.07B | 6.77B | 2.13B | 1.92B | 1.94B | 1.92B | 1.72B | 1.73B | 2.29B | 1.79B | 1.61B | 1.61B | 1.5B | 1.83B | 1.67B | 1.8B | 1.78B | 1.89B | 1.71B | 1.58B | 1.38B | 1.54B | 2.29B | 1.29B | 1.29B | 6.5B | 1.27B | 1.32B | 1.24B | 1.4B | 1.22B | 1.22B | 1.14B | 1.19B | 1.11B | 1.12B | 946M | 1.07B | 1.42B | 981M | 811M |
| Research and Development Revenue Growth | -69.49% | +218.03% | +11.11% | -1.13% | +0.94% | +11.49% | -0.58% | -24.39% | +28.04% | +10.90% | +0.31% | +7.48% | -18.06% | +9.21% | -7.16% | +1.12% | -5.71% | +10.79% | +7.84% | +14.72% | -10.57% | -32.52% | +76.99% | +0.16% | -80.15% | +412.22% | -4.08% | +6.27% | -11.27% | +14.73% | -0.08% | +7.75% | -4.62% | +7.59% | -1.60% | +18.82% | -12.00% | -24.19% | +44.55% | +20.96% | n/a |